Table 2.
Demographic and clinical variables in severe COVID-19 (admission or death) vs. mild or absent COVID-19
| Variable | Severe COVID-19 + (admitted or death) (n: 29) |
Mild COVID-19 + or COVID-19- (n: 182) |
p |
|---|---|---|---|
| Age (y) Mean ± SD | 78 ± 8.7 | 74 ± 9.9 | NS |
| Gender | NS | ||
| Male | 17 (59%) | 107 (59%) | |
| Female | 13 (41%) | 74 (41%) | |
| Duration of disease(y) Mean ± SD | 8.2 ± 6.0 | 8.6 ± 5.6 | NS |
| Institutionalized | 8 (28%) | 9 (5%) | <0.0001 |
| Dementia | 11 (38%) | 27 (15%) | 0.0026 |
| Neoplasm | 3 (10%) | 3 (2%) | 0.0353 |
| Levodopa daily dose (mg) Mean ± SD | 747 ± 5652 | 642.6 ± 415 | NS |
| Dopamine agonists | 5 (17%) | 74 (41%) | 0.0155 |
| MAO-I | 9 (31%) | 92 (51%) | NS |
| Amantadine | 1 (4%) | 22 (12%) | NS |
| Entacapone | 1 (4%) | 19 (11%) | NS |
| Opicapone | 0 | 19 (11%) | NS |
| Advanced therapies | 4 (14%) | 18 (10%) | NS |
| Vitamin D supplementation | 5 (17%) | 43 (23%) | NS |